{
    "Trade/Device Name(s)": [
        "ARK Oxcarbazepine Metabolite Assay",
        "ARK Oxcarbazepine Metabolite Calibrator",
        "ARK Oxcarbazepine Metabolite Control"
    ],
    "Submitter Information": "ARK Diagnostics, Inc.",
    "510(k) Number": "K153596",
    "Predicate Device Reference 510(k) Number(s)": [
        "K010814",
        "K083799"
    ],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "POX",
        "DLJ",
        "LAS"
    ],
    "Summary Letter Date": "July 6, 2016",
    "Summary Letter Received Date": "July 8, 2016",
    "Submission Date": "August 9, 2016",
    "Regulation Number(s)": [
        "21 CFR 862.3645",
        "21 CFR 862.3200",
        "21 CFR 862.3280"
    ],
    "Regulation Name(s)": [
        "Neuroleptic drugs radioreceptor assay test system"
    ],
    "Analyte Class(es)": [
        "chemistry",
        "tdm",
        "toxicology"
    ],
    "Analyte(s)": [
        "Oxcarbazepine Metabolite"
    ],
    "Specimen Type(s)": [
        "Serum"
    ],
    "Specimen Container(s)": [],
    "Instrument(s)/Platform(s)": [
        "Automated clinical chemistry analyzer",
        "Beckman Coulter AU480"
    ],
    "Method(s)/Technology(ies)": [
        "Homogeneous enzyme immunoassay (EIA)",
        "Spectrophotometry"
    ],
    "Methodologies": [
        "Enzyme immunoassay"
    ],
    "Submission Type(s)": [
        "Assay",
        "Calibrator",
        "Control",
        "Reagent",
        "Quality control material"
    ],
    "Document Summary": "FDA 510(k) summary for ARK Oxcarbazepine Metabolite Assay, Calibrator, and Control for quantitative determination of Oxcarbazepine Metabolite in human serum using enzyme immunoassay on automated clinical chemistry analyzers.",
    "Indications for Use Summary": "Quantitative determination of Oxcarbazepine Metabolite in human serum to monitor levels and ensure appropriate therapy; calibrator and control are for calibration and quality control of the assay.",
    "fda_folder": "Toxicology"
}